ChemoCentryx
Market Cap
US$4.5b
Last Updated
2021/01/23 23:18 UTC
Data Sources
Company Financials +
Executive Summary
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has ChemoCentryx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CCXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CCXI's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
3.8%
CCXI
1.8%
US Biotechs
2.3%
US Market
1 Year Return
56.0%
CCXI
45.9%
US Biotechs
23.8%
US Market
Return vs Industry: CCXI exceeded the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: CCXI exceeded the US Market which returned 23.7% over the past year.
Shareholder returns
| CCXI | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.8% | 1.8% | 2.3% |
| 30 Day | 6.4% | 6.7% | 4.8% |
| 90 Day | 9.5% | 24.9% | 14.5% |
| 1 Year | 56.0%56.0% | 48.3%45.9% | 26.6%23.8% |
| 3 Year | 569.4%569.4% | 23.3%16.6% | 45.0%35.4% |
| 5 Year | 1,631.2%1,631.2% | 58.9%46.7% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is ChemoCentryx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?1 month ago | Simply Wall St
Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)1 month ago | Simply Wall St
Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?Valuation
Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?
30.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CCXI ($64.4) is trading below our estimate of fair value ($92.17)
Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CCXI is overvalued based on its PB Ratio (11x) compared to the US Biotechs industry average (4.4x).
Next Steps
Future Growth
How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
49.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.
Revenue vs Market: CCXI's revenue (43.5% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: CCXI's revenue (43.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CCXI is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has ChemoCentryx performed over the past 5 years?
-0.08%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CCXI is currently unprofitable.
Growing Profit Margin: CCXI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 0.08% per year.
Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: CCXI has a negative Return on Equity (-10.13%), as it is currently unprofitable.
Next Steps
Financial Health
How is ChemoCentryx's financial position?
Financial Position Analysis
Short Term Liabilities: CCXI's short term assets ($474.4M) exceed its short term liabilities ($46.9M).
Long Term Liabilities: CCXI's short term assets ($474.4M) exceed its long term liabilities ($81.4M).
Debt to Equity History and Analysis
Debt Level: CCXI's debt to equity ratio (6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CCXI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is ChemoCentryx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CCXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Thomas Schall (61 yo)
24yrs
Tenure
US$3,341,856
Compensation
Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-ba...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD3.34M) is below average for companies of similar size in the US market ($USD5.01M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 24yrs | US$3.34m | 3.34% $ 148.7m | |
| Executive VP | 4.25yrs | US$1.58m | 0.30% $ 13.5m | |
| Senior VP | 16.42yrs | US$1.27m | 0.12% $ 5.5m | |
| Senior Vice President of Human Resources | 0.83yr | no data | no data | |
| Senior Vice President of Clinical Development | 1.75yrs | no data | no data | |
| Senior VP & Head of Commercial | 2yrs | no data | no data | |
| Senior Vice President of Technical Operations | 0.83yr | no data | no data |
2.0yrs
Average Tenure
59yo
Average Age
Experienced Management: CCXI's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 24yrs | US$3.34m | 3.34% $ 148.7m | |
| Independent Director | 4.25yrs | US$257.70k | 0.094% $ 4.2m | |
| Independent Director | 8.58yrs | US$259.40k | 0.019% $ 841.5k | |
| Independent Director | 8.75yrs | US$253.71k | 0.15% $ 6.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$276.05k | 0.20% $ 9.1m | |
| Director | 11.08yrs | US$231.05k | 0.24% $ 10.7m | |
| Independent Director | 1.83yrs | US$434.85k | 0.019% $ 835.7k |
8.6yrs
Average Tenure
64yo
Average Age
Experienced Board: CCXI's board of directors are considered experienced (8.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CCXI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.
Top Shareholders
Company Information
ChemoCentryx, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ChemoCentryx, Inc.
- Ticker: CCXI
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.457b
- Shares outstanding: 69.21m
- Website: https://www.chemocentryx.com
Number of Employees
Location
- ChemoCentryx, Inc.
- 850 Maude Avenue
- Mountain View
- California
- 94043
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CCXI | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2012 |
| 2CX | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2012 |
Biography
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 23:18 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.